All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 8, 2023
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for June 1, 2023

June 1, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Atomvie Global Radiopharma, Telesis Bio, Volitionrx.
Read More
Wesper sleep testing platform

Gasp! Wesper challenges polysomnography with wireless, portable sleep lab

June 1, 2023
By Annette Boyle
No Comments
Wesper Inc., a longitudinal and wireless clinical-grade sleep testing platform, showed ‘exceptional accuracy’ in a head-to-head comparison with polysomnography in a study published in The Journal of Clinical Sleep Medicine. The wireless, longitudinal sleep testing platform had a breathtaking 95% correlation with the cumbersome gold standard test for sleep apnea.
Read More

Brightheart raises €2M for software to detect congenital heart defects in fetuses

June 1, 2023
By Shani Alexander
No Comments
Startup Brightheart SAS raised €2 million (US$2.14 million) in seed financing, from Sofinnova Partners, that will allow the company to accelerate the development of its artificial intelligence software, which helps physicians detect congenital heart defects in fetuses. Brightheart hopes that the technology will improve the detection of complex congenital heart defects during prenatal ultrasound screening as intervening early could address fetal malformations or abnormalities and improve a baby’s chance of survival.
Read More
Australian coins and bills

Immutep to raise AU$80M to advance LAG-3 immunotherapy pipeline

June 1, 2023
By Tamra Sami
No Comments
Immutep Ltd. announced an AU$80 million (US$52.1 million) capital raise that consists of a AU$50 million placement and a AU$30 million entitlement offer to eligible shareholders to fund clinical programs for lead candidate eftilagimod (IMP-321, efti), a lymphocyte activation gene-3 (LAG-3) fusion protein and major histocompatibility complex class II agonist that stimulates both innate and adaptive immunity for treating cancer.
Read More

Eikon-ography? Art of dealmaking on display as three signed, $106M raised

June 1, 2023
By Randy Osborne
No Comments
Having banked almost $775 million since its inception in 2019, Eikon Therapeutics Inc. closed three transactions to beef up its pipeline and raised nearly $106 million in a series C round. And the dealmaking will continue, said Alfred Bowie, chief financial officer. “We still have well over a half-billion in cash on our balance sheet,” he told BioWorld. “We’re active.” The new funds “add more fuel to the fire,” and let the company “make sure we aren’t cannibalizing some of the funding we’ve raised to help push forward the internal pipeline,” which is “advancing very nicely.”
Read More

Hookipa seeks $50M as it prepares to progress HPV cancer drug to phase III

June 1, 2023
By Caroline Richards
No Comments
Hookipa Pharma Inc. is looking to raise about $50 million in a public offering to further advance its lead immunotherapy candidate, HB-200, into a pivotal phase III trial in combination with Keytruda (pembrolizumab, Merck & Co. Inc.) for the first-line treatment of recurrent or metastatic head and neck cancer associated with human papillomavirus (HPV) 16.
Read More

Financings for May 31, 2023

May 31, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Boston Scientific.
Read More

Financings for May 31, 2023

May 31, 2023
No Comments
Biopharmas raising money in public or private financings, including: Anocca, Belite, Cybin, Lynk, Phio, Violet.
Read More

Financings for May 30, 2023

May 30, 2023
No Comments
Med-tech firms raising money in public or private financings, including: Encare, Revamp Medical.
Read More

Heartseed raises ¥2B to continue trials of iPSC-derived cardiomyocytes for heart failure

May 30, 2023
By Tamra Sami
No Comments
Heartseed Inc. raised ¥2 billion (US$14.3 million) in a series D round to continue the phase I/II Lapis trial of its allogeneic induced pluripotent stem cell (iPSC)-derived cardiomyocytes for heart failure. The lead asset, HS-001, is an investigational cell therapy consisting of clusters of purified heart muscle cells (cardiomyocyte spheroids) derived from iPSCs that are designed to restore heart muscle and function in patients with advanced heart failure.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 394 395 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 7, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 7, 2023.
  • Medical cannabis in blister pack of capsules

    Zelira’s stock triples as cannabinoid outperforms Lyrica in pain

    BioWorld
    Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed...
  • Cerebellum, brain stem, spinal cord

    Reprocell reports mixed results for phase II Stemchymal trial in spinocerebellar ataxia

    BioWorld
    Regenerative medicine product Stemchymal, an allogeneic adipose-derived mesenchymal stem cell treatment, missed the primary efficacy endpoints in two phase II...
  • EU flag, pills, syringe

    Otsuka’s schizophrenia drug filing U-turn amongst latest CHMP announcements

    BioWorld
    Otsuka Pharmaceutical Co. Ltd. has gone back on efforts to get its medicine, Asimtufii (aripiprazole), a long-acting maintenance treatment for schizophrenia,...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing